• Leronlimab Combo Shows Promise for Metastatic TNBC in Early Phase 1b/2 Trial Data
  • New Method Using Sound Waves May Stop Breast Cancer Spread in Lymph Nodes, Mouse Study Shows
  • CytoDyn Files for FDA Breakthrough Therapy Status for Leronlimab for Metastatic TNBC
  • Certain Genomic Tests May Soon Be Reimbursable for Breast Cancer Patients in Germany
  • Keytruda, Imprime PGG Combo Increases Overall Survival in Metastatic Triple-negative BC, Data Show
  • Arimidex ‘Highly Effective’ at Reducing Long-term Breast Cancer Rates in At-risk Women, Study Finds
  • Enhertu Gets FDA Approval for Treatment of Advanced HER2-positive Breast Cancer
  • Seattle Genetics Seeks Tucatinib’s Approval by FDA for Advanced HER2-positive Breast Cancer
  • FDA Grants Breakthrough Therapy Status to Tucatinib for Advanced HER2-Positive Breast Cancer
  • TAVO Boosts Responses to Keytruda in Triple-negative Breast Cancer Patients, Interim Phase 2 Data Show
  • Dosing Complete in Phase 2 Trial Evaluating Lymfactin for BC Treatment-Associated Lymphedema
  • Breast Cancer Index Identifies Women Likely to Benefit From Extended Hormone Therapy, Latest Data Show